Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
(2013) In PLoS ONE 8(4).- Abstract
- Impaired olfaction is an early pre-motor symptom of Parkinson's disease. The neuropathology underlying olfactory dysfunction in Parkinson's disease is unknown, however α-synuclein accumulation/aggregation and altered neurogenesis might play a role. We characterized olfactory deficits in a transgenic mouse model of Parkinson's disease expressing human wild-type α-synuclein under the control of the mouse α-synuclein promoter. Preliminary clinical observations suggest that rasagiline, a monoamine oxidase-B inhibitor, improves olfaction in Parkinson's disease. We therefore examined whether rasagiline ameliorates olfactory deficits in this Parkinson's disease model and investigated the role of olfactory bulb neurogenesis. α-Synuclein mice were... (More)
- Impaired olfaction is an early pre-motor symptom of Parkinson's disease. The neuropathology underlying olfactory dysfunction in Parkinson's disease is unknown, however α-synuclein accumulation/aggregation and altered neurogenesis might play a role. We characterized olfactory deficits in a transgenic mouse model of Parkinson's disease expressing human wild-type α-synuclein under the control of the mouse α-synuclein promoter. Preliminary clinical observations suggest that rasagiline, a monoamine oxidase-B inhibitor, improves olfaction in Parkinson's disease. We therefore examined whether rasagiline ameliorates olfactory deficits in this Parkinson's disease model and investigated the role of olfactory bulb neurogenesis. α-Synuclein mice were progressively impaired in their ability to detect odors, to discriminate between odors, and exhibited alterations in short-term olfactory memory. Rasagiline treatment rescued odor detection and odor discrimination abilities. However, rasagiline did not affect short-term olfactory memory. Finally, olfactory changes were not coupled to alterations in olfactory bulb neurogenesis. We conclude that rasagiline reverses select olfactory deficits in a transgenic mouse model of Parkinson's disease. The findings correlate with preliminary clinical observations suggesting that rasagiline ameliorates olfactory deficits in Parkinson's disease. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3733955
- author
- Petit, Géraldine LU ; Berkovich, Elijahu ; Hickery, Mark ; Kallunki, Pekka ; Fog, Karina ; Fitzer-Attas, Cheryl and Brundin, Patrik LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- PLoS ONE
- volume
- 8
- issue
- 4
- article number
- e60691
- publisher
- Public Library of Science (PLoS)
- external identifiers
-
- wos:000318840100095
- pmid:23573275
- scopus:84875692205
- pmid:23573275
- ISSN
- 1932-6203
- DOI
- 10.1371/journal.pone.0060691
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neuronal Survival (013212041)
- id
- 132462da-27d7-4942-9efb-68f5666740d5 (old id 3733955)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23573275?dopt=Abstract
- date added to LUP
- 2016-04-01 13:21:47
- date last changed
- 2022-05-15 04:50:47
@article{132462da-27d7-4942-9efb-68f5666740d5,
abstract = {{Impaired olfaction is an early pre-motor symptom of Parkinson's disease. The neuropathology underlying olfactory dysfunction in Parkinson's disease is unknown, however α-synuclein accumulation/aggregation and altered neurogenesis might play a role. We characterized olfactory deficits in a transgenic mouse model of Parkinson's disease expressing human wild-type α-synuclein under the control of the mouse α-synuclein promoter. Preliminary clinical observations suggest that rasagiline, a monoamine oxidase-B inhibitor, improves olfaction in Parkinson's disease. We therefore examined whether rasagiline ameliorates olfactory deficits in this Parkinson's disease model and investigated the role of olfactory bulb neurogenesis. α-Synuclein mice were progressively impaired in their ability to detect odors, to discriminate between odors, and exhibited alterations in short-term olfactory memory. Rasagiline treatment rescued odor detection and odor discrimination abilities. However, rasagiline did not affect short-term olfactory memory. Finally, olfactory changes were not coupled to alterations in olfactory bulb neurogenesis. We conclude that rasagiline reverses select olfactory deficits in a transgenic mouse model of Parkinson's disease. The findings correlate with preliminary clinical observations suggesting that rasagiline ameliorates olfactory deficits in Parkinson's disease.}},
author = {{Petit, Géraldine and Berkovich, Elijahu and Hickery, Mark and Kallunki, Pekka and Fog, Karina and Fitzer-Attas, Cheryl and Brundin, Patrik}},
issn = {{1932-6203}},
language = {{eng}},
number = {{4}},
publisher = {{Public Library of Science (PLoS)}},
series = {{PLoS ONE}},
title = {{Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.}},
url = {{https://lup.lub.lu.se/search/files/3325997/4019146.pdf}},
doi = {{10.1371/journal.pone.0060691}},
volume = {{8}},
year = {{2013}},
}